Nuo Therapeutics, Inc. (AURX) — SEC Filings
Nuo Therapeutics, Inc. (AURX) — 21 SEC filings. Latest: 10-K (Mar 30, 2026). Includes 8 8-K, 6 10-Q, 3 10-K.
View Nuo Therapeutics, Inc. on SEC EDGAR
Overview
Nuo Therapeutics, Inc. (AURX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Nuo Therapeutics, Inc. (AURX) reported significant revenue growth in its 2025 fiscal year, with product revenues increasing from approximately $1.4 million in 2024 to $3.1 million in 2025, driven by increased adoption of its Aurix System for chronic wound care. A key strategic development was the Di
Sentiment Summary
Across 21 filings, the sentiment breakdown is: 2 bearish, 18 neutral, 1 mixed. The dominant filing sentiment for Nuo Therapeutics, Inc. is neutral.
Filing Type Overview
Nuo Therapeutics, Inc. (AURX) has filed 3 10-K, 8 8-K, 6 10-Q, 3 SC 13G/A, 1 SC 13G with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (21)
Risk Profile
Risk Assessment: Of AURX's 17 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $3.1 million |
Key Executives
- Flynn James E
Industry Context
Nuo Therapeutics operates in the advanced wound care market, a segment focused on innovative treatments for chronic conditions. This market includes advanced dressings, devices, and biological therapies. The company's Aurix System competes by leveraging autologous platelet-rich plasma (PRP) to stimulate natural healing, a strategy aligned with the growing trend towards regenerative medicine in healthcare.
Top Tags
10-Q (4) · Medical Devices (3) · Biotechnology (3) · AURX (3) · financials (3) · Going Concern (2) · Net Loss (2) · 10-K (2) · material-agreement (2) · healthcare (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenues | $3.1 million | Increased from $1.4 million in 2024 to $3.1 million in 2025, representing 121% growth |
| Upfront Distribution Fee | $1.5 million | Paid by Smith+Nephew to Nuo Therapeutics for distribution rights |
| Additional Fees | $750,000 | Eligible to be paid by Smith+Nephew based on reimbursement milestones |
| CMS National Average Reimbursement Rate | $2,108 | Per treatment for Aurix System in hospital outpatient departments (POS 22) for 2026 |
| Third-Party Entity and Individual Representatives | 200 | Number of contractual relationships established by Nuo Therapeutics as of December 31, 2025 |
| Initial Term | 5 years | Duration of the Distribution Agreement with Smith+Nephew |
| Aggregate Market Value of Voting Common Equity | $41.1 million | Held by non-affiliates as of June 30, 2025 |
| Shares Outstanding | 48,289,296 | Of common stock as of March 26, 2026 |
| Total Revenue | $2.22M | Increased 128.4% for the nine months ended September 30, 2025, from $970,301 in 2024. |
| Net Loss | $1.93M | Widened for the nine months ended September 30, 2025, from $1.83M in 2024. |
| Accumulated Deficit | $34.2M | Increased as of September 30, 2025, highlighting persistent unprofitability. |
| Cash | $514,797 | Low cash balance as of September 30, 2025, contributing to going concern doubt. |
| Revenue Growth | 128.4% | Percentage increase in total revenue for the nine months ended September 30, 2025, compared to 2024. |
| Distribution Fee Revenue | $1.5M | Upfront payment from Smith+Nephew, a key driver of revenue growth. |
| Selling, General and Administrative Expenses | $3.47M | Increased for the nine months ended September 30, 2025, contributing to net loss. |
Forward-Looking Statements
- {"claim":"Deerfield Mgmt, L.P. will maintain a significant stake in Nuo Therapeutics, Inc. for the foreseeable future.","entity":"Deerfield Mgmt, L.P.","targetDate":"2025-12-31","confidence":"medium"}
- {"claim":"Nuo Therapeutics, Inc. will continue to be listed under the CUSIP 67059V209.","entity":"Nuo Therapeutics, Inc.","targetDate":"2024-12-31","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Nuo Therapeutics, Inc. (AURX)?
Nuo Therapeutics, Inc. has 21 recent SEC filings from Feb 2024 to Mar 2026, including 8 8-K, 6 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AURX filings?
Across 21 filings, the sentiment breakdown is: 2 bearish, 18 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Nuo Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Nuo Therapeutics, Inc. (AURX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Nuo Therapeutics, Inc.?
Key financial highlights from Nuo Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for AURX?
The investment thesis for AURX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Nuo Therapeutics, Inc.?
Key executives identified across Nuo Therapeutics, Inc.'s filings include Flynn James E.
What are the main risk factors for Nuo Therapeutics, Inc. stock?
Of AURX's 17 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Nuo Therapeutics, Inc.?
Recent forward-looking statements from Nuo Therapeutics, Inc. include guidance on {"claim":"Deerfield Mgmt, L.P. will maintain a significant stake in Nuo Therapeutics, Inc. for the foreseeable future.", and 1 other predictions.